A Study to Evaluate LY3154207 on the Brain of Healthy Participants

A Single-Dose Study Using Functional Magnetic Resonance Imaging to Evaluate the Effect of LY3154207 in Healthy Subjects

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04258826

Enrollment

Registered

2020-02-06

Start date

2021-01-15

Completion date

2022-01-28

Last updated

2022-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Brief summary

The purpose of this study is to learn more about how LY3154207 affects the brain of healthy participants by using magnetic resonance imaging. The study will last up to about nine weeks for each participant and may include up to four visits to the study center.

Interventions

DRUGLY3154207

LY3154207 administered orally.

DRUGPlacebo

Placebo administered orally.

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

BASIC_SCIENCE

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

-Overtly healthy males and non-childbearing females, as determined through medical history and physical examination

Exclusion criteria

* Have known or ongoing psychiatric disorders * Have contraindications to magnetic resonance imaging (MRI)

Design outcomes

Primary

Measure	Time frame	Description
Change from Baseline in Intrinsic Functional Connectivity Among Resting-State Networks of the Brain	Day 1, Approximately Day 28	Mean Connectivity and Mean Component Weight Between LY3154207 and Placebo in the Dorsal Attention Network (DAN), Frontoparietal Network (FPN), and Executive Control Network (ECN).

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026